PMID- 14559799
OWN - NLM
STAT- MEDLINE
DCOM- 20031203
LR  - 20071114
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 63
IP  - 19
DP  - 2003 Oct 1
TI  - Ferredoxin reductase: pharmacogenomic assessment in colorectal cancer.
PG  - 6170-3
AB  - Ferredoxin reductase (FDXR) is a putative contributor to TP53-mediated apoptosis 
      from 5-fluorouracil chemotherapy through the generation of oxidative stress. With 
      TaqMan real-time quantitative reverse transcription-PCR, this study established a 
      significant difference in FDXR relative RNA expression level between tumor 
      (median, 212.9 units) and normal tissues (median, 113.8 units) from 51 colorectal 
      cancer patients (P < 0.001). Seven single nucleotide polymorphisms (SNPs) in the 
      FDXR gene were discovered, with no significant difference in variant allele 
      frequency between colon tumor and normal tissues (P > 0.05), and the common 
      haplotypes for FDXR were not different between colon tumor and normal samples. No 
      correlation was observed between FDXR genotype and RNA expression implying that 
      the polymorphisms described in this study are not regulating FDXR expression in 
      colon cancer. This genomic characterization provides the foundation for 
      pharmacogenetic analysis of the impact of FDXR on chemotherapy for colorectal 
      cancer.
FAU - Yu, Jinsheng
AU  - Yu J
AD  - Department of Medicine, Washington University School of Medicine and the Siteman 
      Cancer Center, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
FAU - Marsh, Sharon
AU  - Marsh S
FAU - Ahluwalia, Ranjeet
AU  - Ahluwalia R
FAU - McLeod, Howard L
AU  - McLeod HL
LA  - eng
GR  - P30 CA 91842/CA/NCI NIH HHS/United States
GR  - U01 GM 63340/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (RNA, Neoplasm)
RN  - EC 1.18.1.2 (Ferredoxin-NADP Reductase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Colorectal Neoplasms/drug therapy/*enzymology/genetics/pathology
MH  - Female
MH  - Ferredoxin-NADP Reductase/*biosynthesis/genetics
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide
MH  - RNA, Neoplasm/biosynthesis/genetics
EDAT- 2003/10/16 05:00
MHDA- 2003/12/04 05:00
CRDT- 2003/10/16 05:00
PHST- 2003/10/16 05:00 [pubmed]
PHST- 2003/12/04 05:00 [medline]
PHST- 2003/10/16 05:00 [entrez]
PST - ppublish
SO  - Cancer Res. 2003 Oct 1;63(19):6170-3.